Puma Biotechnology Inc Cash Flow Conversion Efficiency
Puma Biotechnology Inc cash flow conversion efficiency. Based on the latest financial reports, Puma Biotechnology Inc (PBYI) has a cash flow conversion efficiency ratio of 0.111x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($14.42 Million) by net assets ($130.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Puma Biotechnology Inc (2007–2025)
Cash flow conversion efficiency of Puma Biotechnology Inc from 2007 to 2025. This chart illustrates how Puma Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Puma Biotechnology Inc stock quote for real-time trading data and today's change.
Puma Biotechnology Inc Cash Flow Conversion Ratio Explained
Puma Biotechnology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Puma Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Puma Biotechnology Inc ranked by their cash flow conversion efficiency. Also see PBYI market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cedar Development Co Ltd
SHE:002485
|
-0.052x |
|
Ronshin Group A
SHE:301231
|
N/A |
|
Smcp SAS
PA:SMCP
|
0.110x |
|
Home Invest Belgium - Sifi
BR:HOMI
|
0.024x |
|
Shenzhen Zqgame
SHE:300052
|
0.010x |
|
Thonburi Healthcare Grp Pcl
BK:THG
|
0.024x |
|
Methode Electronics Inc
NYSE:MEI
|
0.007x |
|
PARKEN Sport & Entertainment
CO:PARKEN
|
0.252x |
Annual Cash Flow Conversion Efficiency for Puma Biotechnology Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Puma Biotechnology Inc from 2007 to 2025. Review Puma Biotechnology Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.34 Million | $41.80 Million | 0.321x | -24.08% |
| 2024-12-31 | $92.12 Million | $38.92 Million | 0.422x | -16.41% |
| 2023-12-31 | $53.44 Million | $27.01 Million | 0.505x | +169.00% |
| 2022-12-31 | $21.61 Million | $-15.83 Million | -0.732x | +91.32% |
| 2021-12-31 | $-2.45 Million | $20.65 Million | -8.442x | -6180.06% |
| 2020-12-31 | $-5.95 Million | $800.00K | -0.134x | -110.49% |
| 2019-12-31 | $17.46 Million | $22.38 Million | 1.281x | +282.40% |
| 2018-12-31 | $34.31 Million | $-24.10 Million | -0.703x | +78.29% |
| 2017-12-31 | $53.30 Million | $-172.50 Million | -3.236x | -379.22% |
| 2016-12-31 | $209.82 Million | $-141.70 Million | -0.675x | +9.95% |
| 2015-12-31 | $206.01 Million | $-154.50 Million | -0.750x | -13.71% |
| 2014-12-31 | $117.05 Million | $-77.20 Million | -0.660x | -0.63% |
| 2013-12-31 | $83.99 Million | $-55.05 Million | -0.655x | -92.03% |
| 2012-12-31 | $128.91 Million | $-44.00 Million | -0.341x | -916.91% |
| 2011-12-31 | $54.37 Million | $-1.83 Million | -0.034x | +99.97% |
| 2009-12-31 | $138.00 | $-16.82K | -121.848x | -2340.50% |
| 2008-12-31 | $-2.18K | $-11.83K | 5.438x | -- |
| 2007-12-31 | $0.00 | $-15.09 Million | x | -- |
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more